Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cypher Select, Cypher · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | CYPHER SELECT™ Sirolimus-eluting Coronary Stent |
| 2 | ACTIVE_COMPARATOR | CYPHER™ Sirolimus-eluting Coronary Stent |
| Name | Type | Description |
|---|---|---|
| Cypher Select | DEVICE | CYPHER SELECT™ Sirolimus-eluting Coronary Stent |
| Cypher | DEVICE | CYPHER™ Sirolimus-eluting Coronary Stent |
Inclusion Criteria: 1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia; 2. Single treatment of de novo lesion in a coronar...
Cypher Select is used for treating coronary artery disease, specifically coronary artery lesions. It is an investigational drug-device combination being studied in patients with this condition. The product is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Cypher Select is being developed by Cardinal Health, Inc., which trades under the ticker CAH. The company is conducting clinical research on this product for the treatment of coronary artery disease. The product is currently in Phase 2 development.
Cypher Select is in Phase 2 clinical development. It is an investigational product for coronary artery disease and is not yet approved. One Phase 2 trial has been completed, involving 102 participants in the United Kingdom.
Cypher Select has one completed Phase 2 clinical trial, NCT00232791, titled "The Study to Compare Cypher Versus Cypher Select in Treating Coronary Artery Lesions." This active-controlled, randomized study enrolled 102 patients with coronary artery disease in the United Kingdom.
Cypher Select is a distinct product being compared against Cypher in clinical trials. The completed Phase 2 study, NCT00232791, directly compared Cypher versus Cypher Select in treating coronary artery lesions, indicating they are separate treatments under evaluation.